一个AI嵌入式,可穿戴的双闭环胰岛素输送系统,用于精确的糖尿病管理
Xuecheng He1,2, Wei Huang1, Wensheng Lin1
1Department of Electrical and Electronic Engineering, The University of Hong Kong, Hong Kong SAR, 999077, China.
Advanced materials (Deerfield Beach, Fla.)
|January 12, 2026
概括
这项研究介绍了DuoLoop,一个双闭环系统,用于更安全的糖尿病管理. 它结合了持续的葡萄糖监测 (CGM) 和对葡萄糖敏感的胰岛素,改善了血糖控制和降低了低血糖风险.
科学领域:
- 生物医学工程 生物医学工程
- 糖尿病 技术 技术
- 可穿戴健康系统可穿戴健康系统
背景情况:
- 在全球范围内,有效的血糖管理至关重要.
- 传统的糖尿病护理通常涉及单独的葡萄糖监测和胰岛素输送.
- 连续血糖监测器 (CGM) 能够实现闭环系统,但由于读数不准确,可能会造成低血糖症,这可能会带来安全风险.
研究的目的:
- 提出和评估一种新的双闭环胰岛素输送系统 (DuoLoop).
- 为了减轻与CGM控制的胰岛素输送系统相关的安全风险.
- 通过提高安全性和有效性,提高精确的糖尿病护理.
主要方法:
- 开发一个双闭环系统,集成CGM控制的胰岛素输送和葡萄糖反应性胰岛素 (GRI) 释放.
- 训练并将定制算法嵌入到可穿戴的CGM中,用于边缘计算.
- 在体内进行初步测试,以评估系统的安全性和性能.
主要成果:
- 在初步的体内试验中,DuoLoop系统的安全性得到了改善.
- 与传统的CGM控制系统 (92.10%) 相比,达到更长的正常血糖持续时间 (98.82%).
- 表明了增强糖尿病管理和患者安全的潜力.
结论:
- 拟议的DuoLoop系统提供了一种有希望的方法,可以在闭环糖尿病管理中减轻低血糖风险.
- 使用定制算法的边缘计算提高了可穿戴糖尿病设备的安全性.
- 杜洛普鼓励部署先进的系统,以提供精确的糖尿病护理.
相关概念视频
Insulin Formulations: Types and Delivery
638
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
638
Insulin: Dosing Regimen and Adverse Effects
670
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
670
Diabetes: Management and Pharmacotherapy
856
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
856
Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K
Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Insulin: The Receptor and Signaling Pathways
2.7K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.7K


